Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23332818 | 0.94 | ATF4 (0.42) | ATF4MAPTL3MBTL1SLC6A4SCN9A | |
| SCHEMBL23332820 | 0.86 | ATF4 (0.47) | ATF4MAPTL3MBTL1SCN9A | |
| SCHEMBL21390247 | 0.78 | ATF4 (0.59) | ATF4 | |
| SCHEMBL23332914 | 0.77 | SCN9A (0.44) | SCN9A | |
| SCHEMBL23332841 | 0.77 | SCN9A (0.46) | SCN9A | |
| SCHEMBL23333260 | 0.76 | SCN9A (0.49) | SCN9A | |
| SCHEMBL23332791 | 0.75 | ATF4 (0.60) | ATF4 | |
| SCHEMBL23332896 | 0.75 | SCN9A (0.43) | SCN9A | |
| SCHEMBL23332748 | 0.74 | MAPT (0.39) | ATF4MAPTL3MBTL1SLC6A4SCN9A | |
| SCHEMBL21390176 | 0.74 | ATF4 (0.46) | ATF4SCN9AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885MAPT 3121/4885L3MBTL1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.